The stock performance of Eli Lilly and Company (NYSE: LLY) has been exceptionally good this year, with the pharma giant defying the
Consider these factors before investing in Eli Lilly and Company (LLY)
Categories
Biotechnology
Earnings: Highlights of Eli Lilly’s (LLY) Q3 2022 results
Eli Lilly and Company (NYSE: LLY) on Tuesday reported higher earnings and revenues for the third quarter of 2022. The company also
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2022 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q3 2022 earnings call dated Oct. 27, 2022 Corporate Participants: Susie Lisa -- Senior Vice President, Investor Relations Reshma
BioMarin Pharmaceutical Inc. (BMRN) Q3 2022 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q3 2022 earnings call dated Oct. 26, 2022 Corporate Participants: Traci McCarty -- Vice President of Investor Relations Jean-Jacques
ABBV Infographic: AbbVie’s Q3 earnings beat estimates; revenue up 3%
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a sharp increase in third-quarter adjusted earnings. The bottom line topped expectations, while revenues missed.
Infographic: Highlights of Merck’s (MRK) Q3 2022 earnings
Merck & Co., Inc. (NYSE: MRK) reported a modest increase in adjusted earnings for the third quarter of 2022 when the pharmaceutical
BIIB Stock: Is Biogen an investment worth trying now?
Biogen Inc. (NASDAQ: BIIB) has been going through a rough patch for some time as the company's popular products faced competition and
Bristol Myers Squibb (BMY) Earnings: 3Q22 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.2 billion for the third quarter of 2022, down 3% from the same period
IPO Alert: Third Harmonic files to go public. Here’s what you need to know
IPO activity has started gaining steam after falling significantly in the first half, in line with the global trend, but it is
Jaguar Health, Inc. (JAGX) Q2 2022 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ: JAGX) Q2 2022 earnings call dated Aug. 22, 2022 Corporate Participants: Lisa Conte -- Founder & Chief Executive Officer Carol
Bio Path Holdings Inc. (BPTH) Q2 2022 Earnings Call Transcript
Bio Path Holdings Inc. (NASDAQ: BPTH) Q2 2022 earnings call dated Aug. 16, 2022 Corporate Participants: WIll O'Connor -- Managing Director Peter Nielsen -- President and
Veru Inc. (VERU) Q3 2022 Earnings Call Transcript
Veru Inc. (NASDAQ: VERU) Q3 2022 earnings call dated Aug. 11, 2022 Corporate Participants: Samuel Fisch -- Executive Director, Investor Relations & Corporate Communications
CATALYST PHARMACEUTICALS INC (CPRX) Q2 2022 Earnings Call Transcript
CATALYST PHARMACEUTICALS INC (NASDAQ: CPRX) Q2 2022 earnings call dated Aug. 10, 2022 Corporate Participants: Alicia Grande -- Chief Financial Officer Patrick J. McEnany -- Co-Founder, Chairman,
Cara Therapeutics , Inc. (CARA) Q2 2022 Earnings Call Transcript
Cara Therapeutics , Inc. (NASDAQ: CARA) Q2 2022 earnings call dated Aug. 08, 2022 Corporate Participants: Iris Francesconi -- Chief Strategy Officer and Head
FibroGen, Inc. (FGEN) Q2 2022 Earnings Call Transcript
FibroGen, Inc. (NASDAQ: FGEN) Q2 2022 earnings call dated Aug. 08, 2022 Corporate Participants: Michael Tung -- Vice President of Corporate Strategy and Investor
Moderna, Inc. (MRNA) Q1 2022 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q1 2022 earnings call dated Aug. 03, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Regeneron Pharmaceuticals Inc. (REGN) Q2 2022 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q2 2022 earnings call dated Aug. 03, 2022 Corporate Participants: Ryan Crowe -- Vice President of Investor Relations Leonard
Sage Therapeutics, Inc. (SAGE) Q2 2022 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q2 2022 earnings call dated Aug. 02, 2022 Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief
ImmunoGen, Inc. (IMGN) Q2 2022 Earnings Call Transcript
ImmunoGen, Inc. (NASDAQ: IMGN) Q2 2022 earnings call dated Jul. 29, 2022 Corporate Participants: Anabel Chan -- Head of Investor Relations Mark Enyedy -- President &
Infographic: Key highlights from Biogen (BIIB) Q2 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net income attributable
Despite generic threat, AbbVie (ABBV) remains a good long-term bet
Biopharmaceutical firm AbbVie Inc. (NYSE: ABBV) is currently at a crucial juncture as it strives to overcome the threat from generic competitors